MLICM
STOK icon

Metropolitan Life Insurance Company (MetLife)’s Stoke Therapeutics STOK Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,625
Closed -$21.9K – 1856
2024
Q1 		$21.9K Buy
1,625
+110
+7% +$666 ﹤0.01% 1810
2023
Q4 		$7.97K Hold
1,515
– – ﹤0.01% 2243
2023
Q3 		$5.97K Hold
1,515
– – ﹤0.01% 2382
2023
Q2 		$16.1K Buy
1,515
+255
+20% +$2.71K ﹤0.01% 2050
2023
Q1 		$10.5K Sell
1,260
-142
-10% -$1.28K ﹤0.01% 2142
2022
Q4 		$12.9K Buy
1,402
+77
+6% +$801 ﹤0.01% 2198
2022
Q3 		$17K Hold
1,325
– – ﹤0.01% 2099
2022
Q2 		$17.5K Hold
1,325
– – ﹤0.01% 2104
2022
Q1 		$27.9K Sell
1,325
-4,289
-76% -$85.9K ﹤0.01% 1929
2021
Q4 		$135K Hold
5,614
– – ﹤0.01% 2287
2021
Q3 		$143K Hold
5,614
– – ﹤0.01% 2310
2021
Q2 		$189K Buy
5,614
+1,834
+49% +$64.8K ﹤0.01% 2187
2021
Q1 		$147K Hold
3,780
– – ﹤0.01% 2222
2020
Q4 		$234K Hold
3,780
– – ﹤0.01% 1832
2020
Q3 		$127K Sell
3,780
-1,745
-32% -$49.8K ﹤0.01% 2082
2020
Q2 		$132K Hold
5,525
– – ﹤0.01% 2089
2020
Q1 		$127K Buy
5,525
+2,120
+62% +$52.4K ﹤0.01% 1880
2019
Q4 		$96.4K Buy
+3,405
New +$85.6K ﹤0.01% 2354

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s STOK Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Stoke Therapeutics (STOK) in Q2 2024, closing a stake of 1,625 shares — an estimated $21.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in STOK in Q4 2019 and held it in 18 quarters. The position peaked at $234K in Q4 2020. 114 funds tracked by Wall St. Rank hold STOK as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Stoke Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,625 Stoke Therapeutics shares in Q2 2024, an estimated $21.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Stoke Therapeutics in Q4 2019 and held it in 18 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Stoke Therapeutics position peaked at $234K in Q4 2020.
  • 114 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.